A Trial of HRS-5965 Capsule in Primary IgA Nephropathy
Status:
RECRUITING
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
This multicenter, randomized, double-blind, parallel, placebo-controlled study is being conducted to evaluate the efficacy, and safety of HRS-5965 capsule for primary IgA nephropathy.